NeoGenomics Inc. has issued its full year 2026 financial guidance, projecting revenue between $793 million and $801 million, representing approximately 10% year-over-year growth at the midpoint. Adjusted EBITDA is expected to range from $55 million to $57 million, reflecting a 27-31% increase and about 100 basis points of margin expansion compared to the prior year. Notable drivers include continued momentum in next-generation sequencing $(NGS)$ and contributions from RaDaR and PanTracer LBx products, while non-clinical revenue is anticipated to decline slightly year-over-year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief on February 16, 2026, and is solely responsible for the information contained therein.